In haematology, Biotest’s plasma protein products are used above all in the prophylaxis and acute treatment of haemophilia A and haemophilia B, a blood coagulation disorder.
When people are afflicted with haemophilia, their bodies are unable to stop bleeding on their own. Even small external or internal injuries can have serious consequences; in extreme cases, without proper treatment, patients can bleed to death.
In prophylaxis, those affected receive regular injections of the clotting factor (every two to three days) to prevent haemorrhaging from even starting. Aside from regular medical and injection appointments, these patients can lead an essentially normal life without impairment by the condition. In case of acute hemorrhaging, factor VIII or factor IX preparations are used to stop the bleeding.
Biotest is also developing the monoclonal antibody Indatuximab Ravtansine (BT-062), a drug for use in treating multiple myeloma as well as various other cancers (breast cancer, bladder cancer). This is described in more detail under “Research and development”.
Biotest develops and produces various immunoglobulins in clinical immunology. They are used in the treatment and prophylaxis of disorders of the immune system, which are either inherited or acquired (e.g. through infection or other diseases). In simple terms, immunoglobulins prevent a virus or pathogen from spreading through the body.
Biotest has particular competence with hyperimmunoglobulins used in specific indications. One example is hepatitis B immunoglobulins. They are administered above all before, during and directly after liver transplants due to hepatitis B infection.
With Tregalizumab (BT-061), Biotest is also developing a monoclonal antibody for the treatment of rheumatoid arthritis and psoriasis. This is described in more detail under “Research and development”.
Intensive care medicine
In intensive care and emergency medicine, plasma proteins from Biotest are used for example to correct for loss of blood volume and protein which can occur after serious injuries or burns. Another important therapeutic indication is severe bacterial infections (sepsis) or severe lung infections. In this area in particular, special immunoglobulin preparations such as Pentaglobin® or the IgM concentrate which is still under development, directly save patients´ lives.